Experimental drug DON aims to protect brains of children with cerebral malaria
NCT ID NCT05478720
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This trial evaluates the safety of a single intravenous dose of DON, an experimental drug, in healthy adults, adults with uncomplicated malaria, and children aged 12 months to 14 years with cerebral malaria. Researchers will monitor side effects and measure how the drug moves through the body. In children, they will also check if DON improves blood flow in the brain, reduces brain swelling, or changes brain activity patterns.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DON (6-diazo-5-oxo-L-norleucine)
- What this could lead to
- If safe and effective, DON could become an add-on treatment to reduce brain injury in children with cerebral malaria.
- What could go wrong
- This is an early-phase safety study with small groups, so it may not show clear benefit. Side effects or lack of efficacy could limit further development.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA, CEREBRAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ndirande Research Clinic
COMPLETEDBlantyre, Malawi
-
Queen Elizabeth Central Hospital
RECRUITINGBlantyre, Malawi